Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, May 1999, p. 434-436, Vol. 6, No. 3
Department for General and Marine
Microbiology,
Received 10 August 1998/Returned for modification 19 January
1999/Accepted 24 February 1999
The growth physiology of Escherichia coli during
colonization of the intestinal tract was studied with four animal
models: the streptomycin-treated mouse carrying a reduced microflora, the monoassociated mouse with no other microflora than the introduced strain, the conventionalized streptomycin-treated mouse, and the conventionalized monoassociated mouse harboring a full microflora. A
23S rRNA fluorescent oligonucleotide probe was used for hybridization to whole E. coli cells fixed directly after being taken
from the animals, and the respective growth rates of E. coli BJ4 in the four animal models were estimated by correlating
the cellular concentrations of ribosomes with the growth rate of the
strain. The growth rates thus estimated from the ribosomal content of E. coli BJ4 in vivo did not differ in the
streptomycin-treated and the monoassociated mice. After
conventionalization there was a slight decrease of the bacterial growth
rates in both animal models.
Bacterial colonization of the
mammalian gut plays two important roles. On one hand, it provides
protection against pathogens and carries out digestive processes. On
the other hand, it is a prerequisite of virulence for many pathogenic
bacteria. The intestinal tract represents a complex ecosystem,
harboring 400 to 500 different bacterial species. Densities of up to
1012 bacteria per g of contents have been reported (1,
5). This indigenous flora constitutes a highly competitive
environment and a colonization barrier (3, 6, 8, 20, 24),
which decreases the probability that ingested bacteria will be able to
establish themselves in the intestinal ecosystem of a healthy host. It
is important to understand how bacteria colonize the gut, how they find
their optimal niche, and how they may be excreted as a consequence of
the appearance of a new organism having more effective colonization
factors, such as specific adhesion capacity, better utilization of
nutrients, or faster growth (9).
In order to examine the influence of the microflora on the growth of a
single species, four different animal models were investigated: germfree mice, streptomycin-treated mice, conventionalized germfree mice, and conventionalized streptomycin-treated mice. Germfree mice
have no intestinal microflora and are excellent models for studies of
single bacteria since there is no competition from other bacterial
species, which makes it very easy for an incoming bacterium to
establish itself, proliferate, and persist in the gastrointestinal
tract at a high density. A streptomycin-treated mouse is a conventional
mouse which is treated with streptomycin, after which most facultative
aerobic, gram-negative rods, normally constituting only 0.1 to 1% of
the flora, are removed (10). This is sufficient to remove
the colonization barrier for incoming enteric bacteria, such as
Escherichia coli, which will grow quickly to a level of
107 to 108 CFU/g of feces; this level is 10- to
50-fold lower than levels found in monoassociated animals but still
104-fold higher than those found in conventional animals
(10, 19). Conventionalized mice received oral inoculation of
a homogenate containing cecal contents from a conventional mouse.
In the present investigation (as in previous investigations
[13, 18, 19]), we have monitored colonization and
excretion of E. coli BJ4 in mouse intestines. E. coli BJ4 was originally isolated from a healthy Wistar rat at the
Institute of Toxicology, National Food Agency, Copenhagen, Denmark. A
streptomycin-resistant isolate which was found to be identical to its
parental strain with respect to biochemical reactions and serology was
used (12). The influence of the normal microflora on this
bacterial species in a conventional gastrointestinal environment was
investigated by addition of a complete mouse intestinal flora to
monoassociated and inoculated, streptomycin-treated mice.
The strong correlation between cell growth rate and rRNA content
(2, 11, 21) makes it possible to use quantitative in situ
hybridization with fluorescent rRNA probes to estimate growth rates of
single cells (16, 18, 19). For this estimation, an in vitro
standard curve, based on suspended cultures of the organism under
investigation growing at different rates in different media, is
required. The cellular fluorescence of bacteria in samples from the
respective animals was compared to that described by the standard
curve, and generation times were estimated. Detailed protocols for such
determinations have been presented previously (13, 17-19).
Eleven each of germfree and streptomycin-treated, albino, adult male
mice of the NMRI/KI strain were used in the study. The mouse strain
originates from the Institute fur Versuchstierzucht, Hanover, Germany,
and has been inbred for 37 generations at the Department of Medical
Microbial Ecology, Karolinska Institute, Stockholm, Sweden. The
germfree mice were kept under standard conditions (22 ± 2°C;
50% ± 10% relative humidity; light-dark cycle, 12 h-24 h) as
described previously (4). Eleven conventional mice were
given drinking water containing 5 g of streptomycin sulfate per
liter (starting 24 h before the colonization experiment), until
the time of conventionalization (6 days after inoculation). Thereafter,
they received tap water with no streptomycin added.
The germfree mice were orally dosed with a 0.1-ml aliquot of a
stationary-phase E. coli BJ4 suspension containing 5 × 106 CFU/ml. The streptomycin-treated mice were given 0.1 ml
containing 100-fold more cells to ensure colonization. Before oral
dosing, aliquots of homogenized fecal samples (negative controls) were fixed for hybridization (13, 18, 19). Six days after
inoculation, the mice (germfree and streptomycin treated) were
conventionalized per os with 100 µl of a homogenate of cecal contents
isolated from a conventional mouse, diluted 10-fold in 0.9% NaCl. The
homogenate contained 1.3 × 106 E. coli
cells/ml. No streptomycin-resistant colonies were detected in the
homogenate. Two mice of each animal model were sacrificed at 1, 3, and
5 h and on days 7 and 10. On day 15, one mouse of each model was
sacrificed. From each of the sacrificed mice, samples of feces
(excluding the 1-, 3-, and 5-h samplings, since the bacteria reach the
cecum faster than they do the feces), cecal contents, and cecal mucus
were taken for CFU determination and fixation. The cecal samplings were
carried out as described previously (13, 19).
When the ribosomal probe EC 1531, which is specific for E. coli 23S rRNA (18, 19), was used for quantification of
the fluorescence in E. coli BJ4 in fecal samples from the
streptomycin-treated and the monoassociated mice, it was estimated that
the generation time was constant from days 1 to 6 in both animal
models, varying between 70 and 89 min (Fig.
1). This relatively fast growth of E. coli BJ4 in the two animal models is consistent with
previous findings for streptomycin-treated mice (19). After
inoculation with a normal cecal flora on day 6, the estimated
generation times of the E. coli cells increased to 130 min
for the streptomycin-treated and 116 min for the monoassociated mice on
day 15. Statistical analysis revealed that the increasing trend was
significant, although weak. The similarity of the estimated growth
rates of E. coli BJ4 in monoassociated mice and
streptomycin-treated mice indicates that the large number of bacteria
in the streptomycin-treated mice had no influence on the growth of the
E. coli BJ4 strain.
The population sizes of E. coli BJ4 had reached steady
states of 1.2 × 1010 CFU/g of feces in the
monoassociated mice and 7.1 × 108 CFU/g in the
streptomycin-treated mice by day 6 (Fig.
2). At day 6 after inoculation, the mice
were conventionalized with a normal cecal flora, leading to a fast
reduction of E. coli BJ4 levels in both animal models. The
decrease in BJ4 levels in the monoassociated mice was particularly
high; the number of CFU per gram was reduced from 1.2 × 1010 to a new stable level of 2.1 × 105
in 8 days (Fig. 2), a drop of 4 orders of magnitude, consistent with
the studies by Freter et al. (9). However, in the same time
period, in conventionalized streptomycin-treated mice (Fig. 2) the BJ4
level dropped less than 100-fold to a level of 107 CFU/g.
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Estimation of Growth Rates of Escherichia
coli BJ4 in Streptomycin-Treated and Previously Germfree Mice
by In Situ rRNA Hybridization
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References

View larger version (18K):
[in a new window]
FIG. 1.
Estimated generation times (means ± standard
errors of the means) of E. coli BJ4 in feces from
streptomycin-treated (closed circles) and the monoassociated (open
circles) mice, as determined by hybridization of fixed fecal samples.
Animals were orally inoculated with E. coli BJ4 on day 0. On
day 6, they were conventionalized by oral inoculation of a homogenate
containing cecal contents from a conventional mouse.

View larger version (17K):
[in a new window]
FIG. 2.
Observed concentration of E. coli BJ4 cells
before and after conventionalization of streptomycin-treated (closed
circles) and monoassociated (open circles) mice. Mice were
conventionalized on day 6 by oral inoculation of a homogenate
containing cecal contents from a conventional mouse.
The prevalent theory as to how bacteria colonize the mammalian gut is that all species can coexist as long as each member of the flora is able to utilize one or a few limiting nutrients better than all the others and that the rate of bacterial growth during the colonization process is greater than the washout rate from the intestine (8, 9). It is also possible for a species which does not compete well for limiting nutrients to avoid washout and to colonize if it is able to adhere to the intestinal wall (8, 9).
In the streptomycin-treated mouse, E. coli BJ4 should occupy its normal narrow nutrient niche (22, 23) and, once established, be able to compete well with incoming enterics. In the germfree mouse, however, E. coli BJ4 should be free to utilize any nutrient, including many for which it would compete very poorly against normal intestinal residents. Moreover, the flora in the streptomycin-treated mouse should make it more difficult for incoming bacteria to grow and colonize, whereas in the germfree mouse no such barrier exists. Therefore, if the colonization theory is correct, it would be expected that E. coli BJ4 in the streptomycin-treated mouse model would be more resistant to administration of the cecal flora of a conventional mouse than BJ4 would be in the germfree mouse model. This is, in fact, observed in the present experiments (Fig. 2). Since the estimated growth rates of BJ4 in the two models decreased after conventionalization but were essentially identical to each other at all times (Fig. 1), the more rapid loss of BJ4 in the conventionalized germfree mice was independent of growth rate.
The data presented here show that E. coli grows in the mouse gut at rates that are quite similar whether the animal is monoassociated (germfree) or streptomycin treated (clearing the major groups of gram-negative bacteria); i.e., in both models doubling times of about 75 min were observed (Fig. 2). The data also show that in both the streptomycin-treated mouse model and the monoassociated mouse model, the estimated doubling times of E. coli BJ4 increased to between 116 and 130 min by nine days after conventionalization (Fig. 1). In streptomycin-treated mice, E. coli grows well in the intestinal mucus layer, which covers the epithelial cells, but not in the luminal contents in vivo and in vitro (14, 25). Moreover, nonmotile and nonchemotactic E. coli mutants, when parents and mutants are fed simultaneously to streptomycin-treated mice, colonize just as well as their parents (15). Since the intestinal population stays constant, it seems likely that E. coli must grow in the mucus layer at a rate similar to that with which it is sloughed into the luminal contents. If it is assumed that there is no specific adhesion to any permanent surfaces in the intestine (18), the rate of release of the mucus should determine the growth rate of the bacteria. If so, the present experiments suggest that conventionalization leads to a decrease in the rate of mucus sloughing. Alternatively, it is possible that E. coli can grow slower than the rate of mucus sloughing and still maintain a stable population if a large proportion of bacteria is continuously pulled back into the mucus layer as water is resorbed to form fecal pellets. In any event, the decrease in the bacterial growth rate is in fact quite small, and the actual biological impact of such a decrease remains unclear.
The different densities of E. coli in the different mouse models are most likely caused by differences in nutrient availabilities. The spectrum of potential nutrients for one species depends strictly on the competition from the other species present. Finally, growth may be limited to specific parts of the intestinal system in some but not all of the different animal models; for example, it has been found that in germfree mice E. coli grows very well in the intestinal contents, whereas, as stated above, in streptomycin-treated (and most likely also conventional) mice, growth in the contents is severely inhibited (7, 14).
In conclusion, several factors appear to be important in defining the growth conditions for bacteria in an ecosystem like the mouse large intestine, factors such as nutrient availability, flow rates, adhesion to permanent sites, presence of inhibitors, competition from coresidents, etc. The in situ methods useful for characterization of subpopulations of bacteria in complex environments are important tools in building up a better understanding of the significance of these parameters.
| |
ACKNOWLEDGMENTS |
|---|
We thank Anna-Carin Persson and Johannes Bergstedt, Karolinska Institute, for excellent assistance with the animals.
We acknowledge the financial support provided by NorFa (Nordic Academy for Advanced Study), Oslo, Norway.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, The Technical University of Denmark, Building 301, 2800 Lyngby, Denmark. Phone: 45 45 25 25 13. Fax: 45 45 93 28 09. E-mail: sm{at}im.dtu.dk.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Borriello, S. P. 1986. Microbial flora of the gastrointestinal tract, p. 2-16. In M. J. Hill (ed.), Microbial metabolism in the digestive tract. CRC Press, Inc., Boca Raton, Fla. |
| 2. | Bremer, H., and P. P. Dennis. 1996. Modulation of chemical composition and other parameters of the cell by growth rate, p. 1553-1569. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed., vol. 2. ASM Press, Washington, D.C. |
| 3. | Dubos, R., R. W. Schadler, and R. Costello. 1963. Composition, alterations, and effects of the intestinal flora. Fed. Proc. 22:1322-1329. |
| 4. | El-Bayoumy, K., S. S. Hecht, and D. Hoffmann. 1982. Comparative tumor initiating activity on mouse skin of 6-nitrobenzol[a]pyrene, 6-nitrochrysene, 3-nitroperylene, 1-nitropyrene and their parent hydrocarbons. Cancer Lett. 16:333-337[Medline]. |
| 5. | Finegold, S. M., V. L. Sutter, and G. E. Mathisen. 1983. Normal indigenous intestinal flora, p. 3-31. In D. J. Hentges (ed.), Human intestinal microflora in health and disease. Academic Press, New York, N.Y. |
| 6. | Freter, R. 1956. Experimental enteric Shigella and Vibrio infections in mice and guinea pigs. J. Exp. Med. 104:411-418[Abstract]. |
| 7. | Freter, R. 1978. Possible effects of foreign DNA on pathogenic potential and intestinal proliferation of Escherichia coli. J. Infect. Dis. 137:624-629[Medline]. |
| 8. | Freter, R. 1983. Mechanisms that control the microflora in the large intestine, p. 33-54. In D. J. Hentges (ed.), Human intestinal microflora in health and disease. Academic Press, New York, N.Y. |
| 9. |
Freter, R.,
H. Brickner,
J. Fekete,
M. M. Vickerman, and K. E. Carey.
1983.
Survival and implantation of Escherichia coli in the intestinal tract.
Infect. Immun.
39:686-703 |
| 10. | Hentges, D. J. 1983. Role of the intestinal microflora in host defense against infection, p. 311-331. In D. J. Hentges (ed.), Human intestinal microflora in health and disease. Academic Press, New York, N.Y. |
| 11. | Kjeldgaard, N. O., and C. G. Kurland. 1963. The distribution of soluble and ribosomal RNA as a function of growth rate. J. Mol. Biol. 6:341-348. |
| 12. |
Krogfelt, K. A.,
L. K. Poulsen, and S. Molin.
1993.
Identification of coccoid Escherichia coli BJ4 cells in the large intestine of streptomycin-treated mice.
Infect. Immun.
61:5029-5034 |
| 13. | Licht, T. R., K. A. Krogfelt, P. S. Cohen, L. K. Poulsen, J. Urbance, and S. Molin. 1996. Role of lipopolysaccharide in colonization of the mouse intestine by Salmonella typhimurium studied by in situ hybridization. Infect. Immun. 64:3811-3817[Abstract]. |
| 14. | Licht, T. R., T. Tolker-Nielsen, K. Holmstrøm, K. A. Krogfelt, and S. Molin. 1999. Inhibition of Escherichia coli precursor-16S processing by mouse intestinal contents. Environ. Microbiol. 1:23-32. [Medline] |
| 15. |
McCormick, B. A.,
D. C. Laux, and P. S. Cohen.
1990.
Neither motility nor chemotaxis plays a role in the ability of Escherichia coli F-18 to colonize the streptomycin-treated mouse large intestine.
Infect. Immun.
58:2957-2961 |
| 16. | Møller, S., C. S. Kristensen, L. K. Poulsen, J. M. Carstensen, and S. Molin. 1995. Bacterial growth on surfaces: automated image analysis for quantification of growth rate-related parameters. Appl. Environ. Microbiol. 61:741-748[Abstract]. |
| 17. |
Poulsen, L. K.,
G. Ballard, and D. A. Stahl.
1993.
Use of rRNA fluorescence in situ hybridization for measuring the activity of single cells in young and established biofilms.
Appl. Environ. Microbiol.
59:1354-1360 |
| 18. |
Poulsen, L. K.,
F. Lan,
C. S. Kristensen,
P. Hobolth,
S. Molin, and K. A. Krogfelt.
1994.
Spatial distribution of Escherichia coli in the mouse large intestine inferred from rRNA in situ hybridization.
Infect. Immun.
62:5191-5194 |
| 19. |
Poulsen, L. K.,
T. R. Licht,
C. Rang,
K. A. Krogfelt, and S. Molin.
1995.
Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin-treated mice.
J. Bacteriol.
177:5840-5845 |
| 20. | Salminen, S., E. Isolauri, and T. Onnela. 1995. Gut flora in normal and disordered states. Chemotherapy (Basel) 41(Suppl. 1):5-15. |
| 21. |
Schaechter, M.,
O. Maaloe, and N. O. Kjeldgard.
1958.
Dependency on medium and temperature of cell size and chemical composition during balanced growth of Salmonella typhimurium.
J. Gen. Microbiol.
19:592-606 |
| 22. | Sweeney, N. J., P. Klemm, B. A. McCormick, E. Moller-Nielsen, M. Utley, M. A. Schembri, D. C. Laux, and P. S. Cohen. 1996. The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine. Infect. Immun. 64:3497-3503[Abstract]. |
| 23. | Sweeney, N. J., D. C. Laux, and P. S. Cohen. 1996. Escherichia coli F-18 and E. coli K-12 eda mutants do not colonize the streptomycin-treated mouse large intestine. Infect. Immun. 64:3504-3511[Abstract]. |
| 24. | Van der Waaij, D., J. M. Berghuis-de-Vries, and J. E. C. Lekkerkerk-van der Wees. 1971. Colonization resistance of the digestive tract in conventional and antibiotic treated mice. J. Hyg. Camb. 69:405-411. |
| 25. |
Wadolkowski, E. A.,
D. C. Laux, and P. S. Cohen.
1988.
Colonization of the streptomycin-treated mouse large intestine by a human fecal Escherichia coli strain: role of growth in mucus.
Infect. Immun.
56:1030-1035 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»